{"title":"增强耐受性抑郁症:更新药物治疗策略","authors":"Cesario Bellantuono","doi":"10.1016/j.quip.2011.08.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>A significant number of depressed patients has a treatment-resistant depression (TRD). Many clinical trials, as well as the STAR-D study, have shown that in major depression the initial response to treatment with an effective antidepressant drug is often unsatisfactory.</p></div><div><h3>Material and methods</h3><p>The aim of this review is to provide an updated overview of the psychopharmacological options available for the management of TRD.</p></div><div><h3>Results</h3><p>A number of therapeutic strategies such as switch, combination and augmentation has been assessed in TRD. The most widely used involves a combination between a second generation antipsychotic (SGA) and a serotoninergic antidepressant (SSRI-SNRI).</p></div><div><h3>Conclusions</h3><p>SGA augmentation is a safe and effective option for the treatment of resistant depression. Thus far quetiapine is the only drug that has been approved for this purpose in Italy.</p></div>","PeriodicalId":101052,"journal":{"name":"Quaderni Italiani di Psichiatria","volume":"30 3","pages":"Pages 106-114"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.quip.2011.08.001","citationCount":"0","resultStr":"{\"title\":\"La depressione maggiore resistente: update delle strategie di trattamento farmacologico\",\"authors\":\"Cesario Bellantuono\",\"doi\":\"10.1016/j.quip.2011.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>A significant number of depressed patients has a treatment-resistant depression (TRD). Many clinical trials, as well as the STAR-D study, have shown that in major depression the initial response to treatment with an effective antidepressant drug is often unsatisfactory.</p></div><div><h3>Material and methods</h3><p>The aim of this review is to provide an updated overview of the psychopharmacological options available for the management of TRD.</p></div><div><h3>Results</h3><p>A number of therapeutic strategies such as switch, combination and augmentation has been assessed in TRD. The most widely used involves a combination between a second generation antipsychotic (SGA) and a serotoninergic antidepressant (SSRI-SNRI).</p></div><div><h3>Conclusions</h3><p>SGA augmentation is a safe and effective option for the treatment of resistant depression. Thus far quetiapine is the only drug that has been approved for this purpose in Italy.</p></div>\",\"PeriodicalId\":101052,\"journal\":{\"name\":\"Quaderni Italiani di Psichiatria\",\"volume\":\"30 3\",\"pages\":\"Pages 106-114\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.quip.2011.08.001\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Quaderni Italiani di Psichiatria\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0393064511000284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quaderni Italiani di Psichiatria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0393064511000284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
La depressione maggiore resistente: update delle strategie di trattamento farmacologico
Introduction
A significant number of depressed patients has a treatment-resistant depression (TRD). Many clinical trials, as well as the STAR-D study, have shown that in major depression the initial response to treatment with an effective antidepressant drug is often unsatisfactory.
Material and methods
The aim of this review is to provide an updated overview of the psychopharmacological options available for the management of TRD.
Results
A number of therapeutic strategies such as switch, combination and augmentation has been assessed in TRD. The most widely used involves a combination between a second generation antipsychotic (SGA) and a serotoninergic antidepressant (SSRI-SNRI).
Conclusions
SGA augmentation is a safe and effective option for the treatment of resistant depression. Thus far quetiapine is the only drug that has been approved for this purpose in Italy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
